

AI
CONT'

vasculogenesis in the allantoic explant.

26. The method of claim 25 wherein the test compound has a detrimental effect on blood vessel formation.

July 31 27. The method of claim 25 wherein the test compound is a gene product.

Remarks

In the matter of the December 21, 2000 Office Action, applicants strenuously object to the examiner's characterization of claims 21-23. However, applicants have elected to focus on a different restriction group.

Applicants have cancelled pending claims and insert new claims 24-27. These claims are identical to parent application claims 14, 17, 19 and 20 and comprise restriction group III. Applicants now wish to prosecute this restriction group.

Applicants have enclosed a CPA request transmittal and a three month Extension of Time. If other fees are necessary, please charge Deposit Account 17-0055.

Respectfully submitted,

Karen M. Downs

June 19, 2001

By: Jean C. Baker
Jean C. Baker
QUARLES & BRADY LLP
411 East Wisconsin Avenue
Milwaukee, WI 53202
Reg. No.: 35,433
(414) 277-5709